Landmark Study · Journal Article
A multicenter retrospective study of 479 LBCL patients treated with commercial CD19 CAR-T products (axi-cel, tisa-cel, liso-cel) used serial landmark analyses at Day 28, 3, 6, 12, 18, and 24 months to determine when relapse risk declines and sustained remission is achieved. Patients who attained complete response (CR) at early time points had significantly improved progression-free survival. Elevated pre-lymphodepletion LDH was independently associated with inferior PFS and OS across multiple landmarks. The analysis advances understanding of durable remission kinetics, indicating a trend toward cure, though longer follow-up is needed to confirm. Transplant Cell Ther, 2026.
Transplant Cell Ther (PMID 41765136)
Journal Article
A US multicenter network study found that axicabtagene ciloleucel (axi-cel) administered in an outpatient setting, with structured care pathways, prophylactic dexamethasone, and remote patient monitoring, achieved efficacy and safety comparable to inpatient administration. The findings support broader outpatient CAR-T access, reducing costs and improving patient convenience. Real-world evidence confirms feasibility with appropriate safeguards. Transplant Cell Ther, 2026.
Transplant Cell Ther (PMID 41763314)
Journal Article · Phase 2
Phase II trial of BCMA-directed CAR-T in newly diagnosed multiple myeloma (NDMM) patients ineligible for or not proceeding to autologous stem-cell transplant—often due to age or frailty—demonstrated deep responses, opening a novel frontline strategy. This population has historically had limited effective treatment lines. BCMA CAR-T upfront could redefine treatment paradigms for transplant-ineligible patients. JCO, 2026.
JCO (PMID 41759038)
Journal Article
A multicenter retrospective study of 136 patients with R/R follicular lymphoma treated with axi-cel or tisa-cel showed axi-cel achieved higher ORR (96% vs 80%), CRR (88% vs 71%), and longer median PFS (30.5 vs 11.9 months). Rates of CRS were comparable, but ICANS occurred more frequently with axi-cel (42% vs 17%). After inverse probability weighting, efficacy outcomes remained favorable for axi-cel. Real-world data support product selection based on patient risk and toxicity tolerance. Blood Advances, 2026.
Blood Advances (PMID 41747197)